Article
High burden of clonal mast cell disorders and hereditary α-tryptasemia in patients who need Hymenoptera venom immunotherapy.
Allergy - 1 Sept 2024
Korošec Peter, Sturm Gunter J, Lyons Jonathan J, Marolt Tinkara Pirc, Svetina Manca, Košnik Mitja, Zidarn Mihaela, Kačar Mark, Frelih Nina, Lalek Nika, Luzar Ajda Demšar, Zver Samo, Škerget Matevž, Czarnobilska Ewa, Dyga Wojciech, Grle Sanja Popović, Samarzija Miroslav, Arzt-Gradwohl Lisa, Čerpes Urban, Porebski Grzegorz, Pevec Branko, Schadelbauer Eva, Kopač Peter, Šelb Julij, Rijavec Matija
Abstract excerpt
BACKGROUND: In patients who require venom immunotherapy (VIT), there is a need to identify underlying mast cell (MC) disorders since these may affect the risk and severity of future sting reactions and the long-term effectiveness of VIT. METHODS: 1319 individuals with Hymenoptera venom allergy (HVA) who needed VIT from referral centers in Slovenia, Austria, Croatia, and Poland underwent examination for KIT...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
